Tenet Healthcare Corp

THC remains in a Stage 2 Advancing phase within a secular uptrend, supported by an active Lockout Rally and Higher Highs & Higher Lows patterns. Price trades above rising 9/21 EMAs and the 50 DMA with tight tracking, signaling demand dominance. The medium-term tradable bias is bullish, and short-term momentum is reinforced by lockout dynamics. Buy now into pullbacks at the rising EMA confluence near prior congestion.

• ↑Q1 net revenues $5.4B (+7.2% YoY) with 21.6% adj. EBITDA margin.
• ↑USPI segment EBITDA $484M (+6% YoY) driven by high-acuity procedures.
• ↓GuruFocus flags ~11.5% overvaluation; weak book-to-price warns stretched valuation.